Stock listing

Cstone Pharmaceuticals

Selected listing: 2616 · HKEX · HKD · HK

Cstone Pharmaceuticals (HKEX:2616), Health Technology. Latest release Sep 28, 2026: INTERIM REPORT 2026.

2616:HKEXHKDHKUpdated October 2, 2026

Ticker: HKEX:2616
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: HKEX
Currency: HKD

About Cstone Pharmaceuticals

Cstone Pharmaceuticals is a public company listed on the Hong Kong Stock Exchange under the ticker 2616. Cstone focuses on developing innovative therapies for cancer treatment.

Latest news from Cstone Pharmaceuticals

INTERIM REPORT 2026

September 28, 2026

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

August 27, 2026

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

June 25, 2026

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

June 11, 2026

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

May 31, 2026

All Cstone Pharmaceuticals news →

Research Cstone Pharmaceuticals

Cstone Pharmaceuticals company profile

View the public company page for Cstone Pharmaceuticals on 6ix.

Cstone Pharmaceuticals news

Read company news and market updates connected to Cstone Pharmaceuticals.

Cstone Pharmaceuticals investor events

Find investor webinars, events, and replay context for Cstone Pharmaceuticals.